Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Adrenocortical Carcinoma
NCT05563467Phase 2Active, not recruiting
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Jan 2023
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in adrenocortical carcinoma (ACC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Started Jan 2023; status: active, not recruiting.
02
Drugs
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT05563467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563467.